Advanced search
Publication Cover
Current Medical Research and Opinion Volume 22, 2006 - Issue 5
Submit an article Journal homepage
558
Views
187
CrossRef citations to date
0
Altmetric
Original Article

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study

Vasilios G. Athyros Atherosclerosis and Metabolic Syndrome Units, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; Working Group for the Identification and Treatment of Metabolic Syndrome of the Hellenic Atherosclerosis Society, Athens, Greece
,
Dimitri P. Mikhailidis Working Group for the Identification and Treatment of Metabolic Syndrome of the Hellenic Atherosclerosis Society, Athens, Greece; Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, London, UKCorrespondence[email protected]
,
Triandafillos P. Didangelos Working Group for the Identification and Treatment of Metabolic Syndrome of the Hellenic Atherosclerosis Society, Athens, Greece; Diabetes Centre, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; Second Prop. Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
,
Olga I. Giouleme Second Prop. Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; Division of Gastroenterology, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
,
Evangelos N. Liberopoulos Working Group for the Identification and Treatment of Metabolic Syndrome of the Hellenic Atherosclerosis Society, Athens, Greece; Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, London, UK
,
Asterios Karagiannis Working Group for the Identification and Treatment of Metabolic Syndrome of the Hellenic Atherosclerosis Society, Athens, Greece; Second Prop. Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
,
Anna I. Kakafika Working Group for the Identification and Treatment of Metabolic Syndrome of the Hellenic Atherosclerosis Society, Athens, Greece; Second Prop. Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
,
Konstantinos Tziomalos Working Group for the Identification and Treatment of Metabolic Syndrome of the Hellenic Atherosclerosis Society, Athens, Greece; Second Prop. Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
,
Andrew K. Burroughs Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, Royal Free and University College Medical School, London, UK
&
Moses S. Elisaf Working Group for the Identification and Treatment of Metabolic Syndrome of the Hellenic Atherosclerosis Society, Athens, Greece; Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
 show all
Pages 873-883 | Accepted 21 Mar 2006, Published online: 04 Apr 2006

Citations (187)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (26)

Elizabeth M. Lamos, Megan Kristan, Maka Siamashvili & Stephen N. Davis. (2021) Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Review of Clinical Pharmacology 14:7, pages 837-852.
Read now
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou & Vasilios G. Athyros. (2018) The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 12:4, pages 331-339.
Read now
Nazik Elmalaika OS Husain & Mohamed H Ahmed. (2015) Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV/AIDS - Research and Palliative Care 7, pages 1-10.
Read now
Mariana Verdelho Machado & Helena Cortez-Pinto. (2014) Management of fatty liver disease with the metabolic syndrome. Expert Review of Gastroenterology & Hepatology 8:5, pages 487-500.
Read now
Manfredi Rizzo, Giuseppe Montalto & Khalid Al-Rasadi. (2014) Treatment options for managing atherogenic dyslipidemia and fatty liver disease. Expert Opinion on Pharmacotherapy 15:8, pages 1065-1068.
Read now
Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2014) Reaching hypertriglyceridemia goals. Current Medical Research and Opinion 30:3, pages 391-393.
Read now
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis & Dimitri P. Mikhailidis. (2014) Are statins ‘IDEAL’ for non-alcoholic fatty liver disease?. Current Medical Research and Opinion 30:2, pages 229-231.
Read now
Vasilios G Athyros & Dimitri P Mikhailidis. (2013) Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. Clinical Lipidology 8:5, pages 509-512.
Read now
Vasilios G Athyros, Niki Katsiki & Asterios Karagiannis. (2013) Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease. Expert Opinion on Therapeutic Targets 17:7, pages 861-862.
Read now
Vassilios G. Athyros, Niki Katsiki, Michael Doumas, Asterios Karagiannis & Dimitri P. Mikhailidis. (2013) Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Current Medical Research and Opinion 29:10, pages 1263-1274.
Read now
Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis & Dimitri P Mikhailidis. (2013) Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opinion on Investigational Drugs 22:9, pages 1089-1093.
Read now
Mohamed H Ahmed, Ayman Al-Atta & Mahir A Hamad. (2012) The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opinion on Pharmacotherapy 13:13, pages 1901-1909.
Read now
Fernando Bril, Romina Lomonaco & Kenneth Cusi. (2012) The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clinical Lipidology 7:4, pages 471-481.
Read now
Niki Katsiki, Vasilios G Athyros, Asterios Karagiannis & Dimitri P Mikhailidis. (2011) Current treatment for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 12:13, pages 2141-2142.
Read now
Niki Katsiki & Moses Elisaf. (2011) Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease. Current Medical Research and Opinion 27:8, pages 1669-1672.
Read now
Niki Katsiki, Apostolos I. Hatzitolios & Dimitri P. Mikhailidis. (2011) Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘A new kid on the block’?. Annals of Medicine 43:4, pages 249-258.
Read now
Vasilios G. Athyros, Konstantinos Tziomalos, Georgios N. Daskalopoulos, Asterios Karagiannis & Dimitri P. Mikhailidis. (2011) Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. Annals of Medicine 43:3, pages 167-171.
Read now
Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis & Dimitri P Mikhailidis. (2010) Atorvastatin: safety and tolerability. Expert Opinion on Drug Safety 9:4, pages 667-674.
Read now
N Papanas, E Maltezos & DP Mikhailidis. (2009) Metformin: diamonds are forever. Expert Opinion on Pharmacotherapy 10:15, pages 2395-2397.
Read now
V. G. Athyros, A. Karagiannis, A. I. Hatzitolios, K. Paletas, C. Savopoulos, G. Giannoglou & D. P. Mikhailidis. (2009) Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Current Medical Research and Opinion 25:4, pages 971-980.
Read now
E Nakou, TD Filippatos, EN Liberopoulos, AD Tselepis, DN Kiortsis, DP Mikhailidis & MS Elisaf. (2008) Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opinion on Pharmacotherapy 9:10, pages 1629-1639.
Read now
Vasilios G Athyros, Anna I Kakafika, Konstantinos Tziomalos, Asterios Karagiannis & Dimitri P Mikhailidis. (2008) Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?. Expert Opinion on Investigational Drugs 17:7, pages 969-972.
Read now
Kosmas I. Paraskevas & Dimitri P. Mikhailidis. (2008) C-reactive protein (CRP): more than just an innocent bystander?. Current Medical Research and Opinion 24:1, pages 75-78.
Read now
James W Anderson. (2007) Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opinion on Pharmacotherapy 8:11, pages 1733-1742.
Read now
Maria C. Diakou, Evangelos N. Liberopoulos, Dimitri P. Mikhailidis, Epaminondas V. Tsianos, Andrew K. Burroughs & Moses S. Elisaf. (2007) Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence. Scandinavian Journal of Gastroenterology 42:2, pages 139-147.
Read now
Irene F Gazi & Dimitri P Mikhailidis. (2006) Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opinion on Therapeutic Targets 10:6, pages 851-866.
Read now

Articles from other publishers (161)

Bo Zhu, Hao Wu, Kathryn S. Li, Shahram Eisa-Beygi, Bandana Singh, Diane R. Bielenberg, Wendong Huang & Hong Chen. (2023) Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis. Vascular Pharmacology, pages 107249.
Crossref
Shima Dowla Anwar, Christy Foster & Ambika Ashraf. (2023) Lipid Disorders and Metabolic-Associated Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America 52:3, pages 445-457.
Crossref
Haiyan Zhou, Maeda Toshiyoshi,, Wenli Zhao, Ye Zhao & Yan Zhao,. (2023) Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine 102:26, pages e33981.
Crossref
Mona Salarinia, Mohammad Azizi, Worya Tahmasebi & Hadi Khalvandi. (2023) Effect of Eight Weeks of Vitamin D Consumption and Exercise in Water on Liver Enzymes and Mental Health of Women with Type 2 Diabetes. Modern Care Journal 20:3.
Crossref
May G. Akl & Scott B. Widenmaier. (2023) Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma. Frontiers in Cell and Developmental Biology 10.
Crossref
Mohamed Abdallah, Landon Brown, John Provenza, Raseen Tariq, Smitha Gowda & Ashwani K. Singal. (2022) Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Annals of Hepatology 27:6, pages 100738.
Crossref
Chrysoula Boutari, Panagiotis D. Pappas, Dimitrios Anastasilakis & Christos S. Mantzoros. (2022) Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinical Nutrition 41:10, pages 2195-2206.
Crossref
Evangelia S. Makri, Eleftheria Makri & Stergios A. Polyzos. (2022) Combination Therapies for Nonalcoholic Fatty Liver Disease. Journal of Personalized Medicine 12:7, pages 1166.
Crossref
George N. Ioannou, Sum P. Lee, Peter S. Linsley, Vivian Gersuk, Matthew M. Yeh, Yen‐Ying Chen, Yi‐Jen Peng, Moumita Dutta, Gabby Mascarinas, Bruk Molla, Julia Yue Cui & Christopher Savard. (2021) Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. Hepatology Communications 6:4, pages 780-794.
Crossref
Daniele Pastori, Arianna Pani, Arianna Di Rocco, Danilo Menichelli, Gianluca Gazzaniga, Alessio Farcomeni, Laura D'Erasmo, Francesco Angelico, Maria Del Ben & Francesco Baratta. (2021) Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis. British Journal of Clinical Pharmacology 88:2, pages 441-451.
Crossref
Ismini Tzanaki, Aris P Agouridis & Michael S Kostapanos. (2022) Is there a role of lipid-lowering therapies in the management of fatty liver disease?. World Journal of Hepatology 14:1, pages 119-139.
Crossref
Veronika A. Prikhodko, Natalia N. Bezborodkina & Sergey V. Okovityi. (2022) Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 10:2, pages 274.
Crossref
Maria Apostolopoulou & Michael Roden. 2022. Nicht-alkoholische Fettlebererkrankung. Nicht-alkoholische Fettlebererkrankung 211 225 .
Christian L. Horn, Amilcar L. Morales.Christopher Savard, Geoffrey C Farrell & George N. Ioannou. (2021) Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH. Hepatology Communications 6:1, pages 12-35.
Crossref
Niranjani Venkateswaran, Scott Weismiller & Karen Krok. (2021) Recurrent NASH Post-liver Transplant: Implications and Treatment. Current Hepatology Reports 20:4, pages 108-116.
Crossref
Jose D. Torres-Peña, Laura Martín-Piedra & Francisco Fuentes-Jiménez. (2021) Statins in Non-alcoholic Steatohepatitis. Frontiers in Cardiovascular Medicine 8.
Crossref
Danny Orabi, Nathan A. Berger & J. Mark Brown. (2021) Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers 13:14, pages 3473.
Crossref
Michael P. Johnston, Janisha Patel & Christopher D. Byrne. (2021) Update on cardiovascular risk in nonalcoholic fatty liver disease. Current Opinion in Cardiology 36:4, pages 478-486.
Crossref
Walter Masson, Martín Lobo, Gerardo Masson, Graciela Molinero & Paola Casciato. (2021) Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases 31:5, pages 1357-1364.
Crossref
Samar H. Gerges, Sara A. Wahdan, Doaa A. Elsherbiny & Ebtehal El-Demerdash. (2021) Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sciences 271, pages 119220.
Crossref
Margery A. Connelly, Jonathan Velez Rivera, John R. Guyton, Mohammad Shadab Siddiqui & Arun J. Sanyal. (2020) Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 52:4, pages 619-636.
Crossref
Fan-Ge Meng, Xiu-Ning Zhang, Shi-Xuan Liu, Yi-Ran Wang & Tao Zeng. (2020) Roles of peroxisome proliferator-activated receptor α in the pathogenesis of ethanol-induced liver disease. Chemico-Biological Interactions 327, pages 109176.
Crossref
Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu & Yunlun Li. (2020) An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. BioMed Research International 2020, pages 1-12.
Crossref
Ya. M. Vakhrushev, E. V. Suchkova & A. P. Lukashevich. (2020) Evaluation of the effectiveness of differentiated therapy of non-alcoholic fatty liver disease. Terapevticheskii arkhiv 92:2, pages 29-33.
Crossref
Thomas Marjot, Ahmad Moolla, Jeremy F Cobbold, Leanne Hodson & Jeremy W Tomlinson. (2020) Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews 41:1, pages 66-117.
Crossref
Meiqi Fan, Young-Jin Choi, Yujiao Tang, Sung Mun Bae, Hyun Pil Yang & Eun-Kyung Kim. (2019) Efficacy and Mechanism of Polymerized Anthocyanin from Grape-Skin Extract on High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. Nutrients 11:11, pages 2586.
Crossref
George N. Ioannou, Charles S. Landis, Ga‐Young Jin, W. Geoffrey Haigh, Geoffrey C. Farrell, Rahul Kuver, Sum P. Lee & Christopher Savard. (2019) Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis. Hepatology Communications 3:6, pages 776-791.
Crossref
Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun Takyar, Yaron Rotman, Ohad Etzion, Eric Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop, Mohammad Hassan Murad & Mazen Noureddin. (2019) Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 17:4, pages 616-629.e26.
Crossref
Pakkapon Rattanachaisit, Paweena Susantitaphong, Kessarin Thanapirom, Roongruedee Chaiteerakij, Piyawat Komolmit, Pisit Tangkijvanich & Sombat Treeprasertsuk. (2018) Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Asian Biomedicine 12:1, pages 3-13.
Crossref
Niki Katsiki & Dimitri P Mikhailidis. (2018) Lipids: a personal view of the past decade. Hormones 17:4, pages 461-478.
Crossref
Laurie R Braun, Meghan N Feldpausch, Natalia Czerwonka, Julian Weiss, Karen Branch, Hang Lee, Edgar L Martinez-Salazar, Martin Torriani, Craig A Sponseller, Steven K Grinspoon & Takara L Stanley. (2018) Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism 103:11, pages 4176-4186.
Crossref
Kannan Sridharan, Gowri Sivaramakrishnan, Reginald Paul Sequeira & Abdelaziz Elamin. (2018) Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgraduate Medical Journal 94:1116, pages 556-565.
Crossref
Umair Iqbal, Brandon Perumpail, Nimy John, Sandy Sallam, Neha Shah, Waiyee Kwong, George Cholankeril, Donghee Kim & Aijaz Ahmed. (2018) Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases 6:4, pages 87.
Crossref
Monjur Ahmed. 2018. Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment. Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment.
Knut Stokkeland, Christine Takami Lageborn, Anders Ekbom, Jonas Höijer, Matteo Bottai, Per Stål & Karin Söderberg-Löfdal. (2018) Statins and Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease. Basic & Clinical Pharmacology & Toxicology 122:1, pages 104-110.
Crossref
Tingting Du, Xingxing Sun & Xuefeng Yu. (2017) Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease. Lipids in Health and Disease 16:1.
Crossref
Christopher H. Scott, Kuan-Minn Cha, Jason Ngai, Changtao Jiang, Kim Cheng, Rebecca A. Stokes, Kenneth W. K. Ho, Jacob George, Frank J. Gonzalez & Jenny E. Gunton. (2017) Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice. PLOS ONE 12:11, pages e0186543.
Crossref
Jie Ting Tang & Yi Min Mao. (2017) Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. Journal of Digestive Diseases 18:11, pages 607-617.
Crossref
Ya-Hui Ding, Yuan Ma, Lin-Yan Qian, Qiang Xu, Li-Hong Wang, Dong-Sheng Huang & Hai Zou. (2017) Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. Oncotarget 8:36, pages 60673-60683.
Crossref
Fernando Bril, Paola Portillo Sanchez, Romina Lomonaco, Beverly Orsak, Joan Hecht, Fermin Tio & Kenneth Cusi. (2017) Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. The Journal of Clinical Endocrinology & Metabolism 102:8, pages 2950-2961.
Crossref
Diego Lucero, Verónica Miksztowicz, Gisela Gualano, Cristina Longo, Graciela Landeira, Estela Álvarez, Valeria Zago, Fernando Brites, Gabriela Berg, Eduardo Fassio & Laura Schreier. (2017) Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins. Clinica Chimica Acta.
Crossref
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán & Juan Pedro-Botet. (2017) Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico. Clínica e Investigación en Arteriosclerosis 29:4, pages 185-200.
Crossref
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán & Juan Pedro-Botet. (2017) Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. Clínica e Investigación en Arteriosclerosis (English Edition) 29:4, pages 185-200.
Crossref
George N. Ioannou, Savitha Subramanian, Alan Chait, W. Geoffrey Haigh, Matthew M. Yeh, Geoffrey C. Farrell, Sum P. Lee & Christopher Savard. (2017) Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. Journal of Lipid Research 58:6, pages 1067-1079.
Crossref
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis & Christos Mantzoros. (2017) The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 71, pages 17-32.
Crossref
Rosa Lombardi, Simona Onali, Douglas Thorburn, Brian R Davidson, Kurinchi Selvan Gurusamy & Emmanuel Tsochatzis. (2017) Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD). Cochrane Database of Systematic Reviews 2017:4.
Crossref
E.H. Zaremba, O.V. Smalyukh, O.V. Zaremba-Fedchyshyn & O.V. Zaremba. (2017) The use of rosuvastatin and alpha lipoic acid in patients with unstable angina. Acta Medica Leopoliensia 23:1-2, pages 9-14.
Crossref
Stergios A. Polyzos, Elisabetta Bugianesi, Jannis Kountouras & Christos S. Mantzoros. (2017) Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. Metabolism 66, pages 64-68.
Crossref
Samer Gawrieh. 2017. Liver Disorders. Liver Disorders 199 216 .
Fernando Bril & Kenneth Cusi. (2016) Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America 45:4, pages 765-781.
Crossref
W. Timothy Garvey, Jeffrey I. Mechanick, Elise M. Brett, Alan J. Garber, Daniel L. Hurley, Ania M. Jastreboff, Karl Nadolsky, Rachel Pessah-Pollack & Raymond Plodkowski. (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocrine Practice 22, pages 1-203.
Crossref
Stefano Gitto, Ranka Vukotic, Giovanni Vitale, Martina Pirillo, Erica Villa & Pietro Andreone. (2016) Non-alcoholic steatohepatitis and liver transplantation. Digestive and Liver Disease 48:6, pages 587-591.
Crossref
Pushpjeet Kanwar & Kris V. Kowdley. (2016) The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clinics in Liver Disease 20:2, pages 225-243.
Crossref
Kathleen E. Corey & Mary E. Rinella. (2016) Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences 61:5, pages 1387-1397.
Crossref
Janet Lo, Michael T. Lu, Elli A. Kim, Eric Nou, Travis R. Hallett, Jakob Park, Udo Hoffmann & Steven K. Grinspoon. (2016) Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus. Open Forum Infectious Diseases 3:2.
Crossref
Cynthia Herrick, Samira Bahrainy & Edward A. Gill. (2016) Statins and the Liver. Endocrinology and Metabolism Clinics of North America 45:1, pages 117-128.
Crossref
Stefano Ballestri, Fabio Nascimbeni, Dante Romagnoli, Enrica Baldelli & Amedeo Lonardo. (2016) The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Advances in Therapy 33:3, pages 291-319.
Crossref
George N. Ioannou. (2016) The Role of Cholesterol in the Pathogenesis of NASH. Trends in Endocrinology & Metabolism 27:2, pages 84-95.
Crossref
Fan Ping, Xuan Wang, Jing Yang, Mei-cen Zhou, Wei Li, Ling-ling Xu & Yu-xiu Li. (2016) Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1 H-Magnetic Resonance Spectroscopy . International Journal of Endocrinology 2016, pages 1-6.
Crossref
Newaz Hossain, Pushpjeet Kanwar & Smruti R. Mohanty. (2016) A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterology Research and Practice 2016, pages 1-17.
Crossref
Samer Gawrieh & Naga Chalasani. 2016. Alcoholic and Non-Alcoholic Fatty Liver Disease. Alcoholic and Non-Alcoholic Fatty Liver Disease 313 337 .
Silvia M. Ferolla. 2016. Obesity. Obesity 159 179 .
Mohamed Asrih & François R. Jornayvaz. (2015) Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?. Molecular and Cellular Endocrinology 418, pages 55-65.
Crossref
Konstantinos Tziomalos, Vasilios G. Athyros, Paschalis Paschos & Asterios Karagiannis. (2015) Nonalcoholic fatty liver disease and statins. Metabolism 64:10, pages 1215-1223.
Crossref
Sahar Mohamed El-Haggar & Tarek Mohamed Mostafa. (2015) Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. Hepatology International 9:3, pages 471-479.
Crossref
Cynthia Herrick, Samira Bahrainy & Edward A. Gill. (2015) Statins and the Liver. Cardiology Clinics 33:2, pages 257-265.
Crossref
Tao Zhang, Chengqi Zhang, Yongyuan Zhang, Fang Tang, Hongkai Li, Qian Zhang, Haiyan Lin, Shuo Wu, Yanxun Liu & Fuzhong Xue. (2015) Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: A prospective cohort study. Atherosclerosis 240:1, pages 144-148.
Crossref
Fernando Bril, Kwame Ntim, Romina Lomonaco & Kenneth Cusi. 2015. International Textbook of Diabetes Mellitus. International Textbook of Diabetes Mellitus 292 305 .
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano & Tooru Shimosegawa. (2015) Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology Research 45:4, pages 363-377.
Crossref
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano & Tooru Shimosegawa. (2015) Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Journal of Gastroenterology 50:4, pages 364-377.
Crossref
George N. Ioannou, Derrick M. Van Rooyen, Christopher Savard, W. Geoffrey Haigh, Matthew M. Yeh, Narci C. Teoh & Geoffrey C. Farrell. (2015) Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. Journal of Lipid Research 56:2, pages 277-285.
Crossref
Monjur Ahmed. (2015) Non-alcoholic fatty liver disease in 2015. World Journal of Hepatology 7:11, pages 1450.
Crossref
S. Gitto, G. Vitale, E. Villa & P. Andreone. (2015) Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future. Gastroenterology Research and Practice 2015, pages 1-14.
Crossref
Daniele Pastori, Licia Polimeni, Francesco Baratta, Arianna Pani, Maria Del Ben & Francesco Angelico. (2015) The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease 47:1, pages 4-11.
Crossref
Mazen Noureddin, David Alexanian & Neil Kaplowitz. 2015. Lipid Management. Lipid Management 149 173 .
M. Pallayova & S. Taheri. (2014) Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clinical Obesity 4:5, pages 243-253.
Crossref
A. Sahebkar & G. F. Watts. (2014) Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster. Diabetes, Obesity and Metabolism 16:9, pages 780-792.
Crossref
Yan Lu, Xing Liu, Yang Jiao, Xuelian Xiong, E Wang, Xiaolin Wang, Zhijian Zhang, Huijie Zhang, Lingling Pan, Youfei Guan, Dongsheng Cai, Guang Ning & Xiaoying Li. (2014) Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. Journal of Clinical Investigation 124:8, pages 3501-3513.
Crossref
Esther Prince, Farrah B. Lazare, William R. Treem, Jiliu Xu, Jahangir Iqbal, Xiaoyue Pan, Joby Josekutty, Meghan Walsh, Virginia Anderson, M. Mahmood Hussain & Steven M. Schwarz. (2013) ?-3 Fatty Acids Prevent Hepatic Steatosis, Independent of PPAR-? Activity, in a Murine Model of Parenteral Nutrition?Associated Liver Disease. Journal of Parenteral and Enteral Nutrition 38:5, pages 608-616.
Crossref
Kathleen E. Corey & Naga Chalasani. (2014) Management of Dyslipidemia as a Cardiovascular Risk Factor in Individuals With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 12:7, pages 1077-1084.
Crossref
Cynthia Herrick, Marina Litvin & Anne Carol Goldberg. (2014) Lipid lowering in liver and chronic kidney disease. Best Practice & Research Clinical Endocrinology & Metabolism 28:3, pages 339-352.
Crossref
William Peverill, Lawrie Powell & Richard Skoien. (2014) Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. International Journal of Molecular Sciences 15:5, pages 8591-8638.
Crossref
Tao Zhang, Yongyuan Zhang, Chengqi Zhang, Fang Tang, Hongkai Li, Qian Zhang, Haiyan Lin, Shuo Wu, Yanxun Liu & Fuzhong Xue. (2014) Prediction of Metabolic Syndrome by Non-Alcoholic Fatty Liver Disease in Northern Urban Han Chinese Population: A Prospective Cohort Study. PLoS ONE 9:5, pages e96651.
Crossref
Peter Jarčuška, Martin Janičko, Sylvia Dražilová, Gabriela Senajová, Eduard Veselíny, Ján Fedačko, Leonard Siegfried, Pavol Kristian, Michal Tkáč, Daniel Pella, Mária Mareková, Andrea Madarasová Gecková & Pavol Jarčuška. (2014) Gamma-Glutamyl Transpeptidase Level Associated with Metabolic Syndrome and Proinflammatory Parameters in the Young Roma Population in Eastern Slovakia: a Population-Based Study. Central European Journal of Public Health 22:Supplement, pages S43-S50.
Crossref
Konstantinos Tziomalos. (2014) Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World Journal of Hepatology 6:10, pages 738.
Crossref
Mariana Verdelho Machado. (2014) Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology 20:36, pages 12956.
Crossref
Juan P Arab. (2014) Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World Journal of Gastroenterology 20:34, pages 12182.
Crossref
Aaron M. Gusdon, Ke-xiu Song & Shen Qu. (2014) Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective. Oxidative Medicine and Cellular Longevity 2014, pages 1-20.
Crossref
J. Schleicher, R. Guthke, U. Dahmen, O. Dirsch, H.G. Holzhuetter & S. Schuster. (2014) A theoretical study of lipid accumulation in the liver—implications for nonalcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1841:1, pages 62-69.
Crossref
Simona D’Amore, Giuseppe Palasciano & Antonio Moschetta. 2014. A Systems Biology Approach to Study Metabolic Syndrome. A Systems Biology Approach to Study Metabolic Syndrome 27 61 .
Layli Eslami, Shahin Merat, Reza Malekzadeh, Siavosh Nasseri-Moghaddam & Hermineh Aramin. (2013) Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews.
Crossref
Bart Staels, Anne Rubenstrunk, Benoit Noel, Géraldine Rigou, Philippe Delataille, Lesley J. Millatt, Morgane Baron, Anthony Lucas, Anne Tailleux, Dean W. Hum, Vlad Ratziu, Bertrand Cariou & Rémy Hanf. (2013) Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58:6, pages 1941-1952.
Crossref
Vasilios G. Athyros, Niki Katsiki & Asterios Karagiannis. (2013) Nonalcoholic Fatty Liver Disease and Severity of Cardiovascular Disease Manifestations. Angiology 64:8, pages 572-575.
Crossref
Akinobu Nakamura & Yasuo Terauchi. (2013) Lessons from Mouse Models of High-Fat Diet-Induced NAFLD. International Journal of Molecular Sciences 14:11, pages 21240-21257.
Crossref
Angel Brea & José Puzo. (2013) Non-alcoholic fatty liver disease and cardiovascular risk. International Journal of Cardiology 167:4, pages 1109-1117.
Crossref
Andrew Paul DeFilippis, Michael J. Blaha, Seth S. Martin, Robert M. Reed, Steven R. Jones, Khurram Nasir, Roger S. Blumenthal & Matthew J. Budoff. (2013) Nonalcoholic fatty liver disease and serum lipoproteins: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 227:2, pages 429-436.
Crossref
William Nseir & Mahmud Mahamid. (2013) Statins in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Updated Review. Current Atherosclerosis Reports 15:3.
Crossref
Scott S. Malinowski, Jennifer S. Byrd, Allison M. Bell, Marion R. Wofford & Daniel M. Riche. (2013) Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease in Adults. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:2, pages 223-242.
Crossref
Michael S Kostapanos. (2013) Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World Journal of Hepatology 5:9, pages 470.
Crossref
Romina Lomonaco, Nishanth E. Sunny, Fernando Bril & Kenneth Cusi. (2013) Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. Drugs 73:1, pages 1-14.
Crossref
Sten Madsbad. 2013. The Metabolic Syndrome. The Metabolic Syndrome 191 219 .
Madeline Erario & Zobair M. Younossi. 2013. Diet Quality. Diet Quality 61 73 .
Takashi Nakahara, Hideyuki Hyogo, Yuki Kimura, Tomokazu Ishitobi, Koji Arihiro, Hiroshi Aikata, Shoichi Takahashi & Kazuaki Chayama. (2012) Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatology Research 42:11, pages 1065-1072.
Crossref
Anthony S. Wierzbicki & Jude Oben. (2012) Nonalcoholic fatty liver disease and lipids. Current Opinion in Lipidology 23:4, pages 345-352.
Crossref
Lokpal S. Bhatia, Nicholas P. Curzen & Christopher D. Byrne. (2012) Nonalcoholic fatty liver disease and vascular risk. Current Opinion in Cardiology 27:4, pages 420-428.
Crossref
Ki Hoon Han, Seung Woon Rha, Hyun-Jae Kang, Jang-Whan Bae, Byoung-Joo Choi, So-Yeon Choi, Hyeon-Cheol Gwon, Jang-Ho Bae, Bum-Kee Hong, Dong-Hoon Choi & Kyoo-Rok Han. (2012) Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). Journal of Clinical Lipidology 6:4, pages 340-351.
Crossref
William Nseir, Julnar Mograbi & Murad Ghali. (2012) Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies. Digestive Diseases and Sciences 57:7, pages 1773-1781.
Crossref
Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton & Arun J. Sanyal. (2012) The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:7, pages 1592-1609.
Crossref
Naga Chalasani, Zobair Younossi, Joel E Lavine, Anna Mae Diehl, Elizabeth M Brunt, Kenneth Cusi, Michael Charlton & Arun J Sanyal. (2012) The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. American Journal of Gastroenterology 107:6, pages 811-826.
Crossref
Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton & Arun J. Sanyal. (2012) The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:6, pages 2005-2023.
Crossref
Maartje E. Visser, Gilbert Wagener, Brenda F. Baker, Richard S. Geary, Joanne M. Donovan, Ulrich H.W. Beuers, Aart J. Nederveen, Joanne Verheij, Mieke D. Trip, Dick C.G. Basart, John J.P. Kastelein & Erik S.G. Stroes. (2012) Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. European Heart Journal 33:9, pages 1142-1149.
Crossref
Anne Tailleux, Kristiaan Wouters & Bart Staels. (2012) Roles of PPARs in NAFLD: Potential therapeutic targets. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821:5, pages 809-818.
Crossref
Stergios A. Polyzos, Jannis Kountouras, Christos Zavos & Georgia Deretzi. (2012) Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 46:4, pages 272-284.
Crossref
G. Musso, M. Cassader, F. Rosina & R. Gambino. (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55:4, pages 885-904.
Crossref
Kosmas I. Paraskevas, Dimitri P. Mikhailidis, Nikolaos Roussas & Athanasios D. Giannoukas. (2011) Effect of Antiplatelet Agents, Statins, and Other Drugs on Vascular Access Patency Rates. Angiology 63:1, pages 5-8.
Crossref
Marion Peyrou, Pierluigi Ramadori, Lucie Bourgoin & Michelangelo Foti. (2012) PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Research 2012, pages 1-16.
Crossref
Ali Akbar Abolfathi, Daryoush Mohajeri, Ali Rezaie & Mehrdad Nazeri. (2012) Protective Effects of Green Tea Extract against Hepatic Tissue Injury in Streptozotocin-Induced Diabetic Rats. Evidence-Based Complementary and Alternative Medicine 2012, pages 1-10.
Crossref
Stergios A Polyzos, Jannis Kountouras, Efthimia Zafeiriadou, Kalliopi Patsiaoura, Evangelia Katsiki, Georgia Deretzi, Christos Zavos, Georgios Tsarouchas, Pantelitsa Rakitzi & Aristidis Slavakis. (2011) Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. Journal of the Renin-Angiotensin-Aldosterone System 12:4, pages 498-503.
Crossref
Hideyuki Hyogo, Tadashi Ikegami, Katsutoshi Tokushige, Etsuko Hashimoto, Kazuo Inui, Yasushi Matsuzaki, Hironori Tokumo, Fumiaki Hino & Susumu Tazuma. (2011) Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatology Research 41:11, pages 1057-1065.
Crossref
Lorenzo Maroni, Luigina Guasti, Luana Castiglioni, Franca Marino, Sara Contini, Valentina Macchi, Alessandra De Leo, Giovanni Gaudio, Matteo Tozzi, Anna M. Grandi, Marco Cosentino & Achille Venco. (2011) Lipid Targets During Statin Treatment in Dyslipidemic Patients Affected by Nonalcoholic Fatty Liver Disease. The American Journal of the Medical Sciences 342:5, pages 383-387.
Crossref
Maria Tzefos & Jacqueline L. Olin. (2011) 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: A therapeutic controversy. Journal of Clinical Lipidology 5:6, pages 450-459.
Crossref
Fanny LalloyerKristiaan WoutersMorgane BaronSandrine CaronEmmanuelle VallezJonathan VanhoutteEric BaugéRonit Shiri-SverdlovMarten HofkerBart StaelsAnne Tailleux. (2011) Peroxisome Proliferator–Activated Receptor-α Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 31:7, pages 1573-1579.
Crossref
V. G. Athyros, K. Tziomalos, A. Karagiannis & D. P. Mikhailidis. (2011) Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obesity Reviews 12:7, pages 515-524.
Crossref
Mauro Maurantonio, Stefano Ballestri, Maria Rosaria Odoardi, Amedeo Lonardo & Paola Loria. (2011) Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?. Archives of Medical Research 42:5, pages 337-353.
Crossref
Georgios N. Daskalopoulos, Artemis Karkanaki, Asterios Karagiannis, Dimitri P. MikhailidisVasilios G. Athyros. (2011) Is the Risk for Cardiovascular Disease Increased in all Phenotypes of the Polycystic Ovary Syndrome?. Angiology 62:4, pages 285-290.
Crossref
Sarah D. de Ferranti, Sheila Crean, Jill Cotter, Dylan Boyd & Stavroula K. Osganian. (2010) Hypertriglyceridemia in a Pediatric Referral Practice: Experience With 300 Patients. Clinical Pediatrics 50:4, pages 297-307.
Crossref
Kosmas I. ParaskevasAlkistis Pantopoulou, Ioannis S. Vlachos, George Agrogiannis, Dimitrios G. Iliopoulos, Gabriel Karatzas, Dimitrios Tzivras, Dimitri P. Mikhailidis & Despina N. Perrea. (2011) Comparison of Fibrate, Ezetimibe, Low- and High-Dose Statin Therapy for the Dyslipidemia of the Metabolic Syndrome in a Mouse Model. Angiology 62:2, pages 144-154.
Crossref
Niki Katsiki, Dimitri P. Mikhailidis, Vasilios G. Athyros & Asterios Karagiannis. (2011) Alanine Aminotransferase Is Associated With Metabolic Syndrome Independently of Insulin Resistance. Circulation Journal 75:8, pages 2027.
Crossref
Vasilios G Athyros, Konstantinos Tziomalos, Thomas D Gossios, Theodora Griva, Panagiotis Anagnostis, Konstantinos Kargiotis, Efstathios D Pagourelias, Eleni Theocharidou, Asterios Karagiannis & Dimitri P Mikhailidis. (2010) Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. The Lancet 376:9756, pages 1916-1922.
Crossref
Layli Eslami, Shahin Merat, Reza Malekzadeh, Siavosh Nasseri-Moghaddam & Hermineh Aramin. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Yuki Kimura, Hideyuki Hyogo, Sho-ichi Yamagishi, Masayoshi Takeuchi, Tomokazu Ishitobi, Yoshitaka Nabeshima, Koji Arihiro & Kazuaki Chayama. (2010) Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. Journal of Gastroenterology 45:7, pages 750-757.
Crossref
Giovanni Musso, Roberto Gambino, Maurizio Cassader & Gianfranco Pagano. (2010) A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52:1, pages 79-104.
Crossref
G. Musso, R. Gambino & M. Cassader. (2009) Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews 11:6, pages 430-445.
Crossref
E.N Liberopoulos, M Florentin, M.S Elisaf, D.P Mikhailidis & E Tsianos. (2010) Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study. The Open Cardiovascular Medicine Journal 4:1, pages 120-126.
Crossref
Kristiaan Wouters, Marc van Bilsen, Patrick J. van Gorp, Veerle Bieghs, Dieter Lütjohann, Anja Kerksiek, Bart Staels, Marten H. Hofker & Ronit Shiri-Sverdlov. (2010) Intrahepatic cholesterol influences progression, inhibition and reversal of non‐alcoholic steatohepatitis in hyperlipidemic mice. FEBS Letters 584:5, pages 1001-1005.
Crossref
Brian Lam & Zobair M. Younossi. (2010) Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 3:2, pages 121-137.
Crossref
Theodosios D Filippatos. (2010) Combination drug treatment in patients with non-alcoholic fatty liver disease. World Journal of Hepatology 2:4, pages 139.
Crossref
Yuichi Nozaki, Koji Fujita, Masato Yoneda, Koichiro Wada, Yoshiyasu Shinohara, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Kensuke Kubota, Satoru Saito, Tetsuya Mizoue, Naohiko Masaki, Yoji Nagashima, Yasuo Terauchi & Atsushi Nakajima. (2009) Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. Journal of Hepatology 51:3, pages 548-556.
Crossref
Brian A. Hemstreet & Robert MacLaren. (2009) Introduction: Hepatitis. Journal of Pharmacy Practice 22:4, pages 357-358.
Crossref
Piotr Socha, Andrea Horvath, Pietro Vajro, Piotr Dziechciarz, Anil Dhawan & Hania Szajewska. (2009) Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review. Journal of Pediatric Gastroenterology & Nutrition 48:5, pages 587-596.
Crossref
Christian Ott & Roland E. Schmieder. (2009) The role of statins in the treatment of the metabolic syndrome. Current Hypertension Reports 11:2, pages 143-149.
Crossref
P. Matafome, E. Nunes, T. Louro, C. Amaral, J. Crisóstomo, L. Rodrigues, A. R. Moedas, P. Monteiro, A. Cipriano & R. Seiça. (2008) A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. Naunyn-Schmiedeberg's Archives of Pharmacology 379:3, pages 241-251.
Crossref
Giovanni Musso, Roberto Gambino, Giovanni Pacini, Gianfranco Pagano, Marilena Durazzo & Maurizio Cassader. (2009) Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 49:2, pages 426-435.
Crossref
. (2008) Current World Literature. Current Opinion in Lipidology 19:6, pages 600-614.
Crossref
Seng Khee Gan, Leon A Adams & Gerald F Watts. (2008) The trials and tribulations of the treatment of nonalcoholic fatty-liver disease. Current Opinion in Lipidology 19:6, pages 592-599.
Crossref
Hideyuki Hyogo, Susumu Tazuma, Koji Arihiro, Keiko Iwamoto, Yoshitaka Nabeshima, Motoki Inoue, Tomokazu Ishitobi, Michihiro Nonaka & Kazuaki Chayama. (2008) Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57:12, pages 1711-1718.
Crossref
Nora Anderson & Jürgen Borlak. (2008) Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacological Reviews 60:3, pages 311-357.
Crossref
Vasilios G. Athyros, Anna I. Kakafika, Asterios Karagiannis & Dimitri P. Mikhailidis. (2008) Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis 200:1, pages 1-12.
Crossref
Shi-Jun Zhang, Ze-Xiong Chen, Kai-Ping Jiang, Yong-Hua Cheng & Yan-Li Gu. (2008) The effect of QuYuHuaTanTongLuo Decoction on the non-alcoholic steatohepatitis. Complementary Therapies in Medicine 16:4, pages 192-198.
Crossref
Vasilios G. Athyros, Anna I. Kakafika, Asterios Koragiannis & Dimitri P. Mikhalidis. (2008) Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Patients With Diabetes Mellitus and Mixed Dyslipidemia. The American Journal of Cardiology 101:11, pages 1679-1680.
Crossref
Mihai Daniel Onofrei, Kristina L. Butler, Dawn C. Fuke & Heather B. Miller. (2012) Safety of Statin Therapy in Patients with Preexisting Liver Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:4, pages 522-529.
Crossref
Giovanni Musso, Roberto Gambino, Simona Bo, Barbara Uberti, Giampaolo Biroli, Gianfranco Pagano & Maurizio Cassader. (2008) Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome?. Diabetes Care 31:3, pages 562-568.
Crossref
Jorge-Shmuel Delgado. (2008) Evolving trends in nonalcoholic fatty liver disease. European Journal of Internal Medicine 19:2, pages 75-82.
Crossref
Gerald F Watts & Seng Khee Gan. (2008) Nutrition and metabolism: non-alcoholic fatty liver disease – pathogenesis, cardiovascular risk and therapy. Current Opinion in Lipidology 19:1, pages 92-94.
Crossref
Eric R Kallwitz, Alan McLachlan & Scott J Cotler. (2008) Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World Journal of Gastroenterology 14:1, pages 22.
Crossref
Efstathios PapalambrosFragiska Sigala, Sotiris Georgopoulos, Kosmas I. Paraskevas, Ioanna Andreadou, Xaralambos Menenakos, Panagiotis Sigalas, Alexandros L. Papalambros, Georgios Vourliotakis, Athanasios Giannopoulos, Christos Bakoyiannis & Elias Bastounis. (2016) Malondialdehyde as an Indicator of Oxidative Stress During Abdominal Aortic Aneurysm Repair. Angiology 58:4, pages 477-482.
Crossref
Kosmas I. Paraskevas, George Hamilton & Dimitri P. Mikhailidis. (2007) Statins: An essential component in the management of carotid artery disease. Journal of Vascular Surgery 46:2, pages 373-386.e9.
Crossref
N Goenka, S Subramanian, P Weston & J Vora. (2007) Non‐alcoholic fatty liver disease: more than ‘just a bit of fatty liver’. Practical Diabetes International 24:6, pages 305-308.
Crossref
Vasilios G. Athyros, Emmanuel S. Ganotakis, Moses S. Elisaf, Evangelos N. Liberopoulos, Ioannis A. Goudevenos & Asterios Karagiannis. (2007) Prevalence of vascular disease in metabolic syndrome using three proposed definitions. International Journal of Cardiology 117:2, pages 204-210.
Crossref
Markus Neumeier, Johanna Weigert, Andreas Schäffler, Thomas S. Weiss, Christian Schmidl, Roland Büttner, Cornelius Bollheimer, Charalampos Aslanidis, Jürgen Schölmerich & Christa Buechler. (2006) Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochemical and Biophysical Research Communications 350:3, pages 731-735.
Crossref
E. N. Liberopoulos, V. G. Athyros, M. S. Elisaf & D. P. Mikhailidis. (2006) Statins for non-alcoholic fatty liver disease: a new indication?. Alimentary Pharmacology & Therapeutics 24:4, pages 698-699.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.